

Global Pharma Company Partners with Panalogo to Bring Greater Equity to Clinical Trials

11 Indications Analyzed and \$1.1 Million Saved Over 3 Months



Challenge

- Historically, clinical trials have not adequately represented women and minority racial and ethnic groups.
- The epidemiology team of a top ten global pharmaceutical company was tasked with providing prevalence estimates and corresponding age, sex, race and ethnicity distributions for indicated populations to benchmark clinical trial diversity enrollment.



Solution

- Partnering with a Panalogo analyst, the team leveraged the Instant Health Data (IHD) Analytics platform to design and implement the diversity study.
- Prevalence estimates were easily obtained via IHD across databases and indications of interest, identifying benchmarks to bring greater equity to clinical trials.



Insights & Impact

- IHD saved up to \$1.1 million over 3 months vs. outsourcing.
- From September to mid November 2020, IHD enabled the team to rapidly obtain prevalence estimates for 11 separate indications.
- Team was able to benchmark clinical trial recruitment against regularly updated, fast and flexible analytics from IHD.



Clinical Trial Diversity

“With essential support from our Panalogo analyst, we are using IHD as one of our tools to expand how we generate epidemiological data for clinical trial diversity. Our teams are able to benchmark clinical trial recruitment against regularly updated, fast, and flexible analytics from IHD.”

- Director of Epidemiology

